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The role of tubulointerstitial inflammation.
Background. Exploration of the role of tubulointerstitial in-
flammation in experimental chronic renal disease (CRD) is an
essential step to understanding and finding new treatments for
human CRD. Adriamycin nephrosis (AN) is an experimental
analogue of human focal glomerular sclerosis and tubulointer-
stitial inflammation.
Methods. Using murine and rat AN, we have systematically
investigated the pathogenic roles of chemokines, costimula-
tory molecules, and inflammatory cells, such as macrophages
and effector and regulatory T lymphocytes. The profile of
humoral and cellular mediators was studied in vitro and in
vivo. The pathogenic significance of various factors was inves-
tigated by DNA vaccination, leukocyte reconstitution and de-
pletion, retroviral transduction, and blockade with monoclonal
antibodies.
Results. Renal cortical and tubular cell CC-chemokines, in-
cluding MCP-1, RANTES, and MIP-1a, were up-regulated via
mediation of NFjB, and contributed to disease by attract-
ing inflammatory cells into the interstitium. The role of these
chemokines was confirmed by DNA vaccination. CD40-CD40L
costimulation signals were involved in expansion and activa-
tion of the inflammatory infiltrate, whereas PD-1 signals were
inhibitory, and CD28-B7 appeared to have a neutral effect.
Macrophage and CD8+ T cells were shown to be effectors of
injury, whereas CD4+CD25+ and cd T cells acted as regula-
tory cells. FoxP3 transduction was able to convert naı¨ve T cells
to CD4+CD25+ regulatory T cells.
Conclusion. There is a broad range of humoral and cellu-
lar factors involved in the pathogenesis of experimental CRD,
some of which are potential targets for treatment of human
CRD.
In virtually all forms of progressive experimental
and human chronic renal disease (CRD) there is a
prominent inflammatory infiltrate within the interstitial
compartment. The extent of the infiltrate and associated
areas of fibrosis correlates with progressive decline in re-
nal function. Inflammatory cell populations within this
infiltrate are dynamic, with temporal and spatial varia-
tions of pathogenic significance. The superficially bland
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appearance of the infiltrate belies a complex collage of
inflammatory cell subtypes (e.g., macrophages, effector
and regulatory T lymphocytes, B lymphocytes, dendritic
cells, NK cells), each in varying degrees of activation.
Basic research over the past decade or so has provided
many new insights into the mechanisms underlying the
initiation, development, and even demise of the inflam-
matory infiltrate, and how it damages renal parenchyma
and causes progressive loss of function. The implication
in these processes of a broad range of specific effector
molecules has exposed a number of potential targets for
novel strategies to slow disease progression.
Ours is but one of many laboratories worldwide study-
ing basic aspects of tubulointerstitial injury of progres-
sive CRD. This article will describe recent observations
from our laboratory, in particular focusing on obser-
vations of potential therapeutic promise. Rodent adri-
amycin nephropathy (AN) was used as the model of
CRD in many of these studies, which have investi-
gated the pathogenic roles of chemokines, costimulation
pathways, and infiltrating inflammatory cells, including
macrophages, and effector and regulatory T lymphocytes.
CHEMOKINES
Chemokines play a central role in CRD by attracting
mononuclear inflammatory cells to the interstitium, and
by modulating interactions between resident and inflam-
matory cells [1]. Increased expression of chemokines by
tubular epithelial cells, as well as interstitial fibroblasts,
has been demonstrated in both human and animal in-
flamed kidneys [2–5]. The pathogenicity of chemokines
and their receptors in various renal diseases has been
demonstrated by their blockade with specific antibodies
or receptor antagonists [6, 7].
Our laboratory demonstrated that CC-chemokines,
MCP-1, RANTES, and MIP-1a were up-regulated in re-
nal cortex of rats with AN [3]. Transcription of those
chemokines increased one week after adriamycin (ADR)
administration and peaked at week 2. RANTES and
MIP-1a then returned to control levels, whereas MCP-
1 was sustained at high levels until at least week 4. In
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Table 1. Examples of pro- and anti-inflammatory molecules in
adriamycin nephrosis
Proinflammatory Anti-inflammatory
Chemokines/ MCP-1, RANTES, MIP-1a IL-10, TGF-b
cytokines TNF-a, IL-1, PAF, HGF
Costimulatory CD40-CD40L PD-1
Regulatory NFjB, ?AP-1 FoxP3
vitro studies revealed that the MCP-1 expression in rat
proximal tubular epithelial cells (PTC) was induced by
lipopolysaccharide (LPS) and by albumin and transfer-
rin [2]. The induction of MCP-1 transcription was found
to be mediated through activation of NFjB. Inhibition of
NFjB with the antioxidant pyrrolidine dithiocarbamate
reduced LPS-induced MCP-1 and MIP-1a transcription
in PTC in vitro [8], and reduced cortical tubulointerstitial
injury in proteinuric rats in vivo [9]. In contrast, the an-
tioxidants N-acetylcysteine and quercetin reduced NFjB
activation in vitro [8], but failed to do so in vivo and were
not protective in rat AN [3, 10].
To establish the importance of CC-chemokines, par-
ticularly MCP-1, RANTES, and MIP-1a, to the pro-
gression of CRD, a therapeutic strategy targeting those
chemokines using DNA vaccination was developed and
tested. Advantages of DNA vaccination include that it
is not limited by host production of antibodies (Abs) to
therapeutic Abs, and that multiple chemokines and their
receptors may be targeted. DNA vaccines were made by
cloning reverse transcription-polymerase chain reaction
(RT-PCR) products of rat MCP-1, RANTES, and MIP-1a
into a pTarget vector [11]. Modification of rat MCP-1 se-
quence, a maneuver which has been purported to increase
host immune response in other systems, was achieved by
replacing a surface loop region of MCP-1 sequence with
P30 tetanus toxoid helper epitope using primer extension
PCR.
Rats were vaccinated by 4 weekly injections into the
tibialis anterior muscle prior to administration of ADR.
DNA vaccine against MCP-1 and RANTES in combi-
nation significantly reduced proteinuria and increased
creatinine clearance compared with control groups. By
morphometric analysis, the severity of glomerular scle-
rosis was halved, and interstitial infiltration with CD4+,
CD8+, and CD25+ cells and macrophages reduced to
one third to one tenth by DNA vaccination. Anti-MCP1
and RANTES autoantibodies were detected at higher
levels in chemokine DNA vaccinated rats than in control
rats, suggesting that this may be the protective mecha-
nism [11].
The modified MCP-1 DNA vaccine has recently been
tested in rat AN in our laboratory. Vaccination with
modified MCP-1 protected creatinine clearance and re-
duced glomerular sclerosis and interstitial inflammation,
whereas vaccination with unmodified MCP-1 alone was
Table 2. Inflammatory cells in adriamycin nephrosis
Effector Neutral Protective
Macrophage NK cell CD4+CD25+ T cell
CD8+ T cell B cell CD4+ -foxP3 T cell
cd Tcell
? Macrophage
not protective. Modified MCP-1 vaccination significantly
reduced interstitial infiltration of macrophages, which are
believed to be effector cells in AN. Surprisingly, in vacci-
nated rats, not only was the titer of anti-MCP-1 antibody
significantly increased, but also that of anti-MIP-1a. At
present, it is unclear whether this is due to a cross-reaction
of the antibody or another mechanism, such as epitope
spread resulting from the modification. Thus, DNA vacci-
nation with more than one chemokine simultaneously, or
with modified chemokine DNA, protected renal function
and structure.
These experiments have provided clear evidence for
the importance of CC-chemokines in progression of tubu-
lointerstitial inflammation in AN (Table 1). Antioxidants
inhibiting NFjB-dependent chemokine production, or
DNA vaccination with these chemokines are but two of
several strategies for therapeutic targeting of chemokines
in CRD.
COSTIMULATION
Costimulation refers to signals independent of the
antigen receptor that are required for full activation of
lymphocyte [12]. This represents a bidirectional commu-
nication between the antigen presenting cell (APC) and
the lymphocyte, which could result in activation or inhi-
bition of the immune response. Costimulatory molecules
exist as pairs, with a receptor on T cell and a ligand
on APC. In CRD, PTC may serve as “nonprofessional”
APC, whose communication with infiltrating lympho-
cytes may play a role in disease progression. There are two
classes of costimulatory receptors on T cells based on se-
quence homologies: the Ig family including CD28, PD-1,
CTLA-4, and ICOS, with their ligands from the B7 fam-
ily; and the TNF receptor family, including CD40, OX40,
4-1BB, and CD30, with their respective ligands. We have
investigated the roles of some costimulatory molecules in
murine AN [13].
Ligation of CD40 with its ligand (CD40L) is one of
many proinflammatory signals involved in the initia-
tion and maintenance of tubulointerstitial inflammation.
Blockade of CD40-CD40L with the monoclonal anti-
CD40L antibody MR1 was found in our laboratory to
reduce severity of renal injury in the murine AN [13].
CD40 was weakly expressed in tubules of normal mice,
but was increasingly expressed by tubules, interstitium,
and glomeruli as AN progressed. MR1 was administered
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at days 5, 7, 9, and 11 after ADR, and resulted in a sig-
nificant attenuation of the glomerular and tubular injury
seen at day 42. In addition, proteinuria was reduced and
creatinine clearance improved by MR1. There was a sig-
nificant decrease in the number of cortical macrophages
at both 14 and 42 days after ADR, and cortical expression
of MCP-1 and RANTES was significantly reduced at day
42. The role of CD40-CD40L in AN was also investigated
in mice genetically deficient in CD40. CD40 knockout
mice showed milder disease in terms of proteinuria, in-
terstitial expansion, and glomerular injury at day 28 after
ADR than wild-type mice [14]. Together, these studies of
CD40-CD40L provide a strong evidence for its role in the
pathogenesis of AN, and suggest a potential therapeutic
target.
Another study of CTLA4-Fc fusion protein, which pre-
vents the interaction of CD28 and B7, excluded involve-
ment of CD28-B7 costimulation in AN (unpublished
data), but further confirmation is needed by examining
the progression of AN using mice genetically deficient in
either CD28 or B7.
PD-1 is expressed on a subset of thymocytes, and can be
up-regulated on T, B, and myeloid cells upon activation.
PD-L1 (B7-H1) and PD-L2 (B7-DC) have been identi-
fied as ligands for PD-1, which is believed to be involved
in the delivery of inhibitory signals upon engagement of
its ligands in later phases of immune response [15].
In a preliminary study of PD-1 expression in murine
AN, we found a progressive temporal increase in renal
cortical PD-1 mRNA at days 3, 7, 14, and 28. Intensity
of renal cortical PD-1 mRNA expression correlated with
severity of injury, and minimal PD-1 mRNA expression
was found in normal kidney at 4 weeks. Immunohisto-
chemistry showed strong PD-1 staining in the interstitium
of AN renal cortex, which was absent in normal controls.
The anti-PD-1 monoclonal antibody J43, when adminis-
trated on alternate days until day 14, worsened glomeru-
lar and tubulointerstitial injury and creatinine clearance
at week 4 (Table 1). Anti-PD-1 treatment did not alter
the number of infiltrating CD4+ or CD8+T cells, but
the number of interstitial macrophages was remarkably
increased (unpublished data). When anti-PD-1 antibody
was administered only to day 10, it had no effect on the
disease course, consistent with PD-1’s known activity late
in the immune response. If confirmed, these preliminary
data emphasize the importance of timing for interactions
aimed at boosting PD-1 expression. As further confirma-
tion of the importance of PD-1, PD-L1.Ig will be investi-
gated as a potential treatment for CRD.
EFFECTOR CELLS
The interstitial infiltrate of AN and other forms of CRD
consists of a number of different effector cells, including
macrophages, CD4+, and CD8+ T cells (Table 2).
Macrophages have long been suspected to contribute
to loss of renal function and renal fibrosis in CRD [16].
Specifically, tubulointerstitial macrophage accumulation
in CRD correlates with the severity of glomerular and
interstitial lesions and the degree of renal dysfunction.
Macrophages can mediate tissue injury via release of pro-
teolytic enzymes, reactive oxygen species, vasoactive me-
diators, and cytokines. Macrophages also contribute to
fibrosis by producing fibrogenic growth factors [17]. Nev-
ertheless, much remains to be learned about macrophages
in tubulointerstitial injury.
We have examined the role of interstitial macrophages
in AN [18]. SCID mice, which lack functional T and B
cells, can develop AN of a severity similar to that of im-
munocompetent mice. Moreover, the number of intersti-
tial macrophages was decreased along with CD8+ cells in
immunocompetent mice with AN treated with anti-CD8
[19]. These two observations suggested the macrophage
as a cause of interstitial damage in AN. Therefore,
macrophage depletion was investigated in AN using a
monoclonal antibody ED7 directed against CD11b/CD18
integrin, which is expressed by macrophages. Circulat-
ing ED7 positive cells were reduced by approximately
one third, and renal cortical macrophages (ED1 positive
cells) by almost 50%, whether ED7 was administrated
before or after ADR administration. Even so, ED7 re-
duced renal structural and functional injury only when
treatment was commenced prior to ADR administration
(unpublished observation). Among several possible ex-
planations for these observations is a temporal change
in the predominant macrophage phenotype. If patho-
genetic macrophages predominated early and ‘protec-
tive’ macrophages later in the disease course, then only
early antimacrophage treatment would be expected to
protect against progression.
Recent observations from other investigators support
the importance of macrophage phenotype. For exam-
ple, in mice with unilateral ureteric obstruction reconsti-
tuted with marrow of angiotensin II type 1 receptor gene
knockout or wild-type mice, infiltrating macrophages
were shown to play a beneficial antifibrotic role [20].
Other studies have demonstrated marked macrophage
heterogeneity and context specificity, depending on the
nature of the injury and location within the kidney [17].
Further studies on possible temporal variations in the
phenotype, activation status, and net effect on injury of
macrophages should give a better understanding of the
complex role of macrophages in CRD.
CD8+ T cells are regarded as the predominant effec-
tor cells in a number of forms of renal injury, includ-
ing nephrotoxic serum nephritis [21], antitubular base-
ment membrane disease [22] and Heymann nephritis [23].
The role of CD8+ cells in murine AN was examined in
our laboratory [19]. Anti-CD8+ monoclonal antibody
was administered from day 5 after ADR, when overt
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proteinuria was established, and mice were sacrificed at
week 6. Splenic CD8+ cell levels were reduced to <2%
of normal. Anti-CD8+ treatment provided marked pro-
tection against structural and functional injury in AN. As
mentioned above, interstitial macrophage numbers were
also reduced, and so it was not possible to dissect the
relative importance of CD8+ T cells and macrophages
to disease progression in these particular experiments.
Also noteworthy was an apparent, though not statistically
significant, increase in the number of interstitial CD4+
cells, which will be discussed further below. Reconsti-
tution of SCID mice with non-CD4+ T cells (predom-
inantly CD8+ cells) exacerbated AN, consistent with an
effector role of CD8+ cells.
Given the fact that anti-CD8+ treatment may also re-
duce numbers of another effector cell, the NK cell, its pos-
sible role was also investigated. There was no difference in
renal injury in AN following administration of anti-asialo
GM1 antibody which depleted both peripheral and renal
NK cells. This occurred even though the stimulatory NK
cell receptor, NKG2D, and its ligand RAE1, were found
to be up-regulated in AN. It is possible that the NK ac-
tivation signal was overwhelmed by an inhibitory signal
of MHC class I molecule that was found constitutively
expressed in kidney of both normal and AN mice. Sup-
porting the results of NK depletion by antibody, AN in
NOD-SCID mice (which lack NK, T, and B cells) showed
a similar severity in renal injury to that of SCID mice
(which lack T and B cells) [24]. Our findings excluded
NK cells from a significant involvement in the tubuloint-
erstitial inflammation of AN (Table 2).
REGULATORY T CELLS
CD4+ T cells constitute a critical component of the
adaptive immune system, and are typified by their capac-
ity to help both humoral and cell-mediated responses.
However, there is substantial functional diversity among
CD4+ T cells, and it is obvious that certain subpopu-
lations hinder rather than help immune responses. The
most well characterized example of an inhibitory sub-
population is the CD4+CD25+ cell, which appears to
play an active role in down-regulating pathogenic au-
toimmune responses [25]. CD4+CD25+ T cells are po-
tent immunoregulatory cells that not only suppress T-cell
proliferation in vitro, but also have the capacity to sup-
press immune responses to auto- and alloantigens, tumor
antigens, and infectious agents in vivo [26].
We have shown previously that depletion of CD4+ T
cells in established AN aggravated glomerular and inter-
stitial injury [27], suggesting their protective role against
progression of disease. This was further confirmed by re-
constituting SCID mice with CD4+ T cells, which pro-
tected against AN. To determine whether the protective
effect of CD4+ T cells in AN was due to the subset of
CD4+CD25+ T cells, which comprise 5% to 10% of the
total peripheral CD4+ T cell population in normal adult
mice, we reconstituted SCID mice with CD4+CD25+
T cells after induction of AN. Mice reconstituted with
CD4+CD25+ T cells had significantly reduced glomeru-
losclerosis, tubular injury, and interstitial expansion com-
pared to unreconstituted mice with AN (Table 2). Urine
protein levels and serum creatinine were significantly
lower, and creatinine clearance significantly higher in re-
constituted mice. This protective effect of CD4+CD25+
T cells in murine AN raises the possibility that enhance-
ment of CD4+CD25+ regulatory cell activity may be a
useful maneuver for slowing progression of CRD.
cd T cells are an ancient lineage of T cells that play
important roles in antimicrobial immunity, as well as
in chronic inflammatory processes [28]. cd T cells were
found to be expanded in kidneys of rats with Heymann
nephritis (HN) and AN, and to express a restricted set
of Vc6/Vd1 TCR genes. High levels of regulatory cy-
tokines, including TGF-b , IL-4, and IL-5, and low levels
of IL-2 were expressed by the infiltrating cd T cells in
HN [29], but only high levels of TGF-b in AN. The cd T
cells from both AN and HN kidneys expressed NKG2D.
Depletion of cd T cells by mAb in vivo worsened AN
in terms of serum creatinine, glomerulosclerosis, and in-
terstitial inflammation (unpublished data). These results
suggest that in these models cdT cells respond to tissue in-
jury through NKG2D and produce a regulatory response
(Table 2).
Recent studies have indicated that the forkhead/
winged helix transcription factor gene (Foxp3) is specifi-
cally expressed by regulatory T (TR) cells, and programs
their development and function [30, 31]. Currently, we
are developing TR cells by retroviral gene transfer of
Foxp3 to convert naı¨ve T cells toward to a regulatory
T-cell phenotype for use in CRD. Retroviral vectors ex-
pressing Foxp3 and green fluorescent protein (GFP) were
transfected into and produced by package cell lines, and
then transduced into mouse and rat CD4+ T cells, with
an efficiency of 30%. One week after infection, GFP-
positive cells, sorted by flow cytometry, were CD25+ with
enhanced expression of Foxp3, TGF-beta, and CTLA-4,
each a molecule implicated in the regulatory phenotype.
Effective generation of rodent TR from naı¨ve T cells in
vitro and in vivo though retroviral Foxp3 transduction
brings the prospect of a novel approach for treating CRD.
CONCLUSION
These and other studies suggest that in CRD, protein-
uria, and other stimuli may cause up-regulation of CC-
chemokines, particularly MCP-1, RANTES, and MIP-
1a, by the tubular epithelial cells. The up-regulation
of CC-chemokines is mediated particularly through the
transcription factor NFjB. In concert with chemokine
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secretion, costimulatory molecules such as CD40 are
also presented by tubules, interstitium, and glomeruli
of AN mice. Blockade of CD40-CD40L by mAb and
gene knockout proved that the CD40-CD40L pathway
contributes to interstitial inflammation in AN, while the
CD28-B7 pathway appeared not to be involved. In con-
trast, blockade of PD-1 by mAb worsened disease when
continued until at least 2 weeks after disease induction,
demonstrating that it provides an inhibitory signal in
AN. Macrophages and CD8+ T cells were identified
as effector leukocytes in AN, while NK cells were ex-
cluded from playing any important role. As a whole, the
CD4+ T cell population was shown to be protective in
AN, a property which resides, at least in part, in the
CD4+CD25+ subpopulation. The regulatory role of cd
T cells was demonstrated in rat Heymann nephritis and
AN. These observations have revealed a wide range of
pathogenic factors involved in tubulointerstitial inflam-
mation, and identified potential targets for novel ther-
apeutic strategies. Unmodified DNA vaccination with
multiple chemokines (e.g., MCP-1 and RANTES) or
modified DNA vaccination with a single chemokine (e.g.,
MCP-1) has demonstrated promise as a therapeutic strat-
egy. Another novel approach involving transduction of
CD4+ T cells with FoxP3 to develop a functional regula-
tory phenotype in vitro is under investigation, and could
be developed into therapeutic strategy for treating CRD.
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